SG5035

SG5035 is a small molecule antifungal agent being developed by Sungening for the treatment of invasive fungal infections. It functions by inhibiting 1,3-beta-glucan synthase, an enzyme essential for the production of 1,3-beta-D-glucan, which is a key structural component of the fungal cell wall. This mechanism of action is similar to that of the echinocandin class of antifungals; however, SG5035 is a small molecule, whereas echinocandins are typically large cyclic lipopeptides. This structural difference potentially allows for both intravenous and oral administration. As of the latest reports, the injectable formulation of SG5035 has reached the Investigational New Drug (IND) stage, while an oral formulation is in preclinical development at the Pre-Clinical Candidate (PCC) stage.